The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Emmanuel Mignot
Project Title: Analysis of hypocretin/orexin and other biomarkers in the cerebrospinal fluid of Alzheimer and controls patients and for Genome-wide association analysis
Date: December 21, 2021 at 5:02 pm
Request ID: T1619 Mignot
Aim 1: To study the differences of hypocretin metabolism in AD patients vs. controls both at the physiological and at the genetic level
Aim 2:
Aim 3:
Aim 4:
Investigator: Dr. Rosa Rademakers
Project Title: Whole-genome sequencing in FTLD-TDP patients
Date: December 21, 2021 at 5:02 pm
Request ID: T1618
Aim 1: Discovery of novel genetic elements associated with FTLD-TDP
Aim 2: Replication and characterization of novel genetic elements associated with FTLD-TDP
Aim 3:
Aim 4:
Investigator: Amir Levine
Project Title: Identifying non-invasive predictive markers of Alzheimer’s Disease
Date: December 21, 2021 at 5:02 pm
Request ID: T1725
Aim 1: To identify non-invasive molecular markers from frozen EDTA plasma that distinguish subjects with MCI only from those with MCI who convert to AD
Aim 2:
Aim 3:
Aim 4:
Investigator: Tammie Benzinger
Project Title: Association between MRI-based neuroinflammation markers and CSF biomarkers of inflammation
Date: December 21, 2021 at 5:02 pm
Request ID: T1724
Aim 1: To improve and extend the ADRC�s neuroinflammation imaging and biomarker dataset
Aim 2: Validate a novel magnetic resonance imaging (MRI) method, diffusion based spectrum imaging (DBSI), as a biomarker of neuroinflammation in AD
Aim 3: Examine the relationship of DBSI cell signal to neuroinflammation-related CSF biomarkers
Aim 4: Determine the spatial distribution of DBSI which relates best to CSF neuroinflammation biomarkers
Investigator: Chihiro Sato
Project Title: Quantitative analysis of tau phosphorylation and isoforms in Brain, CSF, and cell culture models
Date: December 21, 2021 at 5:02 pm
Request ID: T1722-A
Aim 1: The goal of this pilot experiment is to test the hypothesis that there are no brain regional differences in the phosphorylation profile of soluble tau in Alzheimer’s disease (AD) brain.
Aim 2:
Aim 3:
Aim 4:
Investigator: Dwight German
Project Title: Pesticide exposure and Alzheimer’s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T0912-A
Aim 1: Validate DDE levels in tissue samples from samples previously provided.
Aim 2: Determine whether DDE brain levels are the same in different brain regions
Aim 3:
Aim 4:
Investigator: Tammie Benzinger
Project Title: Quantification of Neuroinflammation inAlzheimer’s Disease Using Diffusion BasisSpectrum Imaging
Date: December 21, 2021 at 5:02 pm
Request ID: T1604-A
Aim 1: Validate DBSI as a biomarker of neuroinflammation in AD by using quantitative neuropathology.
Aim 2: Compare DBSI to PET biomarkers of neuroinflammation (DPA-7148, PBR289, PK1119510) and AD ([18F]-Florbetapir, [18F]-Flortaucipir).
Aim 3: Compare DBSI to CSF biomarkers of neuroinflammation (YKL4011 , sTREM212, 13) and AD (A�42, tau, p-tau)
Aim 4: Quantify cross sectional and longitudinal DBSI cell fraction in preclinical and early symptomatic AD and correlate with clinical outcomes (cognitive and progression).
Investigator: Kevin Yarasheski
Project Title: Analytical validation & confirmation of a novel blood test for brain amyloidosis
Date: December 21, 2021 at 5:02 pm
Request ID: T1723
Aim 1: Conduct the analytical validation of a novel, quantitative mass spectrometry-based plasma A� isoform assay.
Aim 2: Confirm the ability of this novel assay to distinguish between people with/without brain amyloidosis.
Aim 3: Calculate the assay accuracy (ROC AUC) and threshold plasma A�42/A�40 ratio that distinguishes between brain amyloid positive vs negative.
Aim 4:
Investigator: Fujirebio Diagnostics Inc
Project Title: Fujirebio ADRC Sample Request
Date: December 21, 2021 at 5:02 pm
Request ID: T1721
Aim 1: to establish a Lumipulse G β-Amyloid 1-42 assay cutoff for distinguishing AD vs. HC in an autopsy confirmed LOAD population with appropriate clinical data.
Aim 2:
Aim 3:
Aim 4:
Investigator: Sally Temple/Celeste Karch
Project Title: iPSC Modeling of AD Using Progerin
Date: December 21, 2021 at 5:02 pm
Request ID: T1720
Aim 1: Is prelamin A expression and processing perturbed in AD brains?
Aim 2:
Aim 3:
Aim 4: